This mini review highlights how bone marrow hemodilution affects measurable residual disease evaluation in multiple myeloma, suggesting strategies for standardization.
Bone marrow hemodilution could compromise next generation flow cytometry based measurable residual disease evaluation in multiple myeloma and may cause false negative results. This review summarizes definitions, markers, indices, mitigation strategies, and current challenges in standardization.
No takes yet. Share an insight, caveat, or question.
Bădeliță et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: